Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Cicarelli,R.M.B. (2) Barbosa,C.F. (1) Bosetto,M.C. (1) Castro,L.I.R. de (1) Chung,M.C. (1) Ferreira,E.I. (1) Okuda,E.S. (1) Peixoto,M.S. (1) Mais... Palavra-chave Trypanosoma cruzi (2) Autoantibodies (1) Chagas' disease (1) Cross-reactivity (1) HeLa cells (1) Hydroxymethylnitrofurazone (1) Permeable cells (1) RNA processing (1) Small nuclear ribonucleoprotein (1) Trans-splicing (1) Trypanocidal drugs (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2007 (1) 2004 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Presence of autoantibodies against HeLa small nuclear ribonucleoproteins in chagasic and non-chagasic cardiac patients BJMBR Bosetto,M.C.; Peixoto,M.S.; Castro,L.I.R. de; Cicarelli,R.M.B.. We detected anti-human small nuclear ribonucleoprotein (snRNP) autoantibodies in chagasic patients by different immunological methods using HeLa snRNPs. ELISA with Trypanosoma cruzi total lysate antigen or HeLa human U small nuclear ribonucleoproteins (UsnRNPs) followed by incubation with sera from chronic chagasic and non-chagasic cardiac patients was used to screen and compare serum reactivity. Western blot analysis using a T. cruzi total cell extract was also performed in order to select some sera for Western blot and immunoprecipitation assays with HeLa nuclear extract. ELISA showed that 73 and 95% of chronic chagasic sera reacted with HeLa UsnRNPs and T. cruzi antigens, respectively. The Western blot assay demonstrated that non-chagasic cardiac sera... Tipo: Info:eu-repo/semantics/article Palavras-chave: Chagas' disease; Autoantibodies; Small nuclear ribonucleoprotein; Trypanosoma cruzi; HeLa cells; Cross-reactivity. Ano: 2004 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000100006 Rapid test for the evaluation of the activity of the prodrug hydroxymethylnitrofurazone in the processing of Trypanosoma cruzi messenger RNAs BJMBR Barbosa,C.F.; Okuda,E.S.; Chung,M.C.; Ferreira,E.I.; Cicarelli,R.M.B.. No fully effective treatment has been developed since the discovery of Chagas' disease by Carlos Chagas in 1909. Since drug-resistant Trypanosoma cruzi strains are occurring and the current therapy is effectiveness in the acute phase but with various adverse side effects, more studies are needed to characterize the susceptibility of T. cruzi to new drugs. Many natural and/or synthetic substances showing trypanocidal activity have been used, even though they are not likely to be turned into clinically approved drugs. Originally, drug screening was performed using natural products, with only limited knowledge of the molecular mechanism involved in the development of diseases. Trans-splicing, which is unusual RNA processing reaction and occurs in nematodes... Tipo: Info:eu-repo/semantics/article Palavras-chave: Trypanosoma cruzi; Trans-splicing; Trypanocidal drugs; Permeable cells; RNA processing; Hydroxymethylnitrofurazone. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000100005 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco